<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824952</url>
  </required_header>
  <id_info>
    <org_study_id>0432-20-SZMC</org_study_id>
    <secondary_id>0432-20-SZMC</secondary_id>
    <nct_id>NCT02824952</nct_id>
  </id_info>
  <brief_title>Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC</brief_title>
  <official_title>Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC - a Phase 2 Open-label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will receive AZD9291 at a dose of 80 mg once daily. Systemic evaluation will be done&#xD;
      by PET-CT scan after 6 weeks.&#xD;
&#xD;
      In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks. Non-responding&#xD;
      patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of&#xD;
      response assessment at each time-point).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will receive AZD9291 at a dose of 80 mg once daily. Systemic evaluation will be done&#xD;
      by PET-CT scan after 6 weeks.&#xD;
&#xD;
      In responding patients AZD9291 will be given orally 80 mg daily for 12 weeks. Non-responding&#xD;
      patients will receive AZD9291 for the period of 6 or 12 weeks (according to the results of&#xD;
      response assessment at each time-point). All the patients will be followed for 2 years.&#xD;
&#xD;
      The imaging modality used for RECIST v1.1 assessments will be PET-CT scan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate as defined by RECIST 1.1</measure>
    <time_frame>12 weeks</time_frame>
    <description>assessed by PET-CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mPFS measured by Kaplan-Meier method.</measure>
    <time_frame>2 years</time_frame>
    <description>mPFS measured by Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing GTV (Gross tumor volume) before and after the neoadjuvant therapy</measure>
    <time_frame>2 years</time_frame>
    <description>Comparing GTV (Gross tumor volume) before and after the neoadjuvant therapy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Lung Cancer, Non-small Cell</condition>
  <arm_group>
    <arm_group_label>Tagrisso 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 mg of Tagrisso(AZD9291) will be given every day for 6 or 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tagrisso</intervention_name>
    <description>taking orally everyday for 6 or 12 weeks.</description>
    <arm_group_label>Tagrisso 80 mg</arm_group_label>
    <other_name>AZD9291</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria.&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Male or female, aged at least 18 years.&#xD;
&#xD;
          3. Treatment-naïve stage IIIA/B NSCLC with an activating sensitizing EGFR mutation/T790M&#xD;
&#xD;
             • Uncommon sensitizing EGFR mutations are allowed.&#xD;
&#xD;
          4. Measurable disease by RECIST criteria v1.1.&#xD;
&#xD;
          5. Patients are amenable for curative chemo-radiotherapy.&#xD;
&#xD;
          6. ECOG PS 0/1.&#xD;
&#xD;
             •total bilirubin less then 1.5 mg/dL, ALT+ AST levels 3 times above the upper normal&#xD;
             limit.&#xD;
&#xD;
          7. Normal hematologic, renal and liver function:&#xD;
&#xD;
               -  Absolute neutrophil count over 1500/mm3, platelets over 100,000/mm3, hemoglobin&#xD;
                  over 9 g/dL;&#xD;
&#xD;
               -  Creatinine concentration less than 1 mg/dL, or creatinine clearance over 60&#xD;
                  mL/min;&#xD;
&#xD;
               -  Total bilirubin less than 1.5 mg/dL, ALT and AST levels 3 times above the upper&#xD;
                  normal limit.&#xD;
&#xD;
          8. FEV-1 more than1 liter.&#xD;
&#xD;
          9. Female patients with reproductive potential must have a negative pregnancy test&#xD;
             (serum/urine) prior to starting treatment.&#xD;
&#xD;
         10. All patients with reproductive potential must agree to use barrier contraception&#xD;
             methods while receiving the study treatment.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. EGFR TKI - resistant EGFR mutations (e.g., insertion in exon 20)&#xD;
&#xD;
          2. T790M is allowed.&#xD;
&#xD;
          3. Treatment with any of the following:&#xD;
&#xD;
          4. Prior treatment with any systemic anti-cancer therapy for advanced NSCLC;&#xD;
&#xD;
          5. Prior treatment with an EGFR-TKI;&#xD;
&#xD;
          6. Major surgery within 4 weeks of the first dose of study drug;&#xD;
&#xD;
          7. Treatment with an investigational drug within five half-lives of the compound.&#xD;
&#xD;
          8. Pregnant or lactating women.&#xD;
&#xD;
          9. Inability to sign the informed consent form.&#xD;
&#xD;
         10. Any concurrent and/or other active malignancy that has required systemic treatment&#xD;
             within 2 years of first dose of study drug.&#xD;
&#xD;
         11. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled&#xD;
             hypertension and active bleeding diatheses; or active infection including hepatitis B,&#xD;
             hepatitis C and human immunodeficiency virus (HIV), uncontrolled diabetes.&#xD;
&#xD;
         12. Inability to swallow the formulated product, malabsorption syndrome, refractory nausea&#xD;
             and vomiting that would preclude adequate absorption of AZD9291.&#xD;
&#xD;
         13. Any of the following cardiac criteria:&#xD;
&#xD;
         14. Mean resting corrected QT interval (QTc) &gt;470 msec, obtained from 3 consequent ECGs,&#xD;
             using the screening clinic ECG machine-derived QTc value;&#xD;
&#xD;
         15. Any clinically important abnormalities in rhythm, conduction, or morphology of resting&#xD;
             ECG;&#xD;
&#xD;
         16. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events,&#xD;
             including unexplained sudden death under 40 years of age in a first-degree relative,&#xD;
             or any concomitant medication known to prolong the QTc interval.&#xD;
&#xD;
         17. Any evidence/past medical history of interstitial lung disease (ILD) or radiation&#xD;
             pneumonitis which required steroid treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nir Peled, MD PhD FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nir Peled, MD PhD FCCP</last_name>
    <phone>+972 0 587040620</phone>
    <email>nirp@szmc.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nir Peled, MD PhD FCCP</last_name>
      <email>nirp@szmc.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>July 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaare Zedek Medical Center</investigator_affiliation>
    <investigator_full_name>Nir Peled</investigator_full_name>
    <investigator_title>Head of Oncology</investigator_title>
  </responsible_party>
  <keyword>Tagrisso</keyword>
  <keyword>AZD9291</keyword>
  <keyword>EGFRm</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

